323990 — Vaxcell Bio Therapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩412bn
- KR₩362bn
- KR₩14m
Annual income statement for Vaxcell Bio Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 13.7 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | 0 | 7.13 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4,011 | 4,255 | 5,904 | 8,217 | 11,520 |
| Operating Profit | -4,011 | -4,255 | -5,904 | -8,217 | -11,507 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -111 | -229 | -246 | -350 | -524 |
| Dividends per Share |